Form 4: Axsome Therapeutics COO Executes Planned Stock Option Exercises and Sales

Axsome Therapeutics' Chief Operating Officer, Mark L. Jacobson, reported the exercise of stock options and subsequent sale of common stock totaling 40,673 shares over two days in late May, pursuant to a pre-approved 10b5-1 trading plan.

Summary

• Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics, Inc. (AXSM), reported transactions involving the company's common stock.
• On May 27, 2025, Mr. Jacobson exercised stock options for 20,673 shares at an exercise price of $6.47 per share.
• Immediately following the option exercise on May 27, 2025, he sold all 20,673 shares at a weighted average sale price of $104.66 per share, with individual sales ranging from $103.96 to $106.44.
• On May 28, 2025, Mr. Jacobson exercised additional stock options for 20,000 shares, also at an exercise price of $6.47 per share.
• Subsequently, on May 28, 2025, he sold all 20,000 shares obtained from the option exercise at a weighted average sale price of $103.45 per share, with individual sales ranging from $102.67 to $104.22.
• Both sets of transactions (option exercises and subsequent sales) were conducted under a pre-approved Rule 10b5-1 trading plan.
• The stock options exercised were nearing their 10-year expiration date, which would occur within 12 months.
• Following these transactions, Mr. Jacobson's direct beneficial ownership of Axsome Therapeutics common stock is 5,783 shares, and his beneficial ownership of derivative securities (stock options) is 0.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it's a pre-planned transaction (10b5-1) for exercising expiring options, which is a common and expected event for executives to monetize their compensation. It does not suggest a negative outlook on the company's future.

Positives

• The transactions were executed under a pre-approved 10b5-1 plan, indicating a pre-scheduled and non-discretionary sale, which often mitigates negative interpretations of insider selling.
• The significant difference between the exercise price ($6.47) and the sale prices ($104.66 and $103.45) indicates substantial gains for the reporting person from vested options.

Negatives

• The sale of a significant number of shares by a Chief Operating Officer, even if pre-planned, reduces the insider's direct equity stake in the company.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook. It solely reports past insider transactions.

Management Comments

• "Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within 12 months."
• "Such transaction was pursuant to a pre-approved 10b5-1 plan."
• "Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options."

Industry Context

This filing is a routine disclosure of insider trading activity, specifically the exercise of expiring stock options and subsequent sale of shares. It does not provide broader industry context or trends, but such transactions are common for executives monetizing vested equity compensation.

Stakeholder Impact

• Shareholders: May note the reduction in the COO's direct shareholding, but the 10b5-1 plan context suggests a routine financial planning event rather than a signal of lack of confidence.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Mark L. Jacobson, 10b5-1 Plan, Equity Compensation